An open label randomized comparative clinical trial on Efficacy and Safety of Bilastine tablet, Fluticasone and Mometasone nasal spray in allergic rhinitis; A tertiary care hospital based prospective interventional study. - NI

INDIRA GANDHI MEDICAL COLLEGE0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年11月13日

试验速览

暂无简介。

•1.All allergic rhinitis diagnosed patients attending ENT OPD irrespective of type of allergic rhinitis.
•2.Patients aged 18-50 years of either sex will be enrolled for the study.
•3.Written informed Consent.
•4.Adequate literacy to complete the dairy card.

•1.Patients with acute or chronic sinusitis, chronic purulent postnasal drip, rhinitis sicca, atrophic rhinitis, rhinitis medicamentosa. nasal structure abnormalities, including nasal ulceration, nasal mucosal erosion, large nasal polyps, marked septal deviations, or recent nasal surgery that would have significantly interfered with nasal air flow.
•2.Hypersensitivity to Bilastine, Fluticasone, Mometasone and/or any other drug of same class.
•3.Patients with an active pulmonary disorder including asthma, upper respiratory tract or sinus infection that required antibiotic therapy within 14 days of the screening visit or an upper respiratory trat infection/ocular infection within 7 days of screening visit.
•4.Patients with the history of narrow-angle glaucoma, increased intraocular pressure, and posterior sub capsular cataract.
•5.Patients with RBS of >140mg/dl, serum transminases of twice upper normal limit, serum bilirubin of >2.0mg/dl, and/or serum creatnine >2.5mg/dl.
•6.Pregnant or lactating females.
•7.Pateints who had received the following medications in the given time frame; nasal/oral decongestants, nasal/antihistamines; 72 hours; nasal/inhaled corticosteriods, leukotriene receptor antagonists, 5-lipooxygenase inhibitors, methylxanthines, nonprescription drugs; 7days; MOA inhibitors: 14 days; oral corticosteroids ;12 weeks.

发起方